Last reviewed · How we verify
ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
Approved treatments
- Inluriyo · Eli Lilly And Co
Inluriyo works by blocking estrogen receptors on cancer cells, preventing them from growing and spreading.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer patent landscape — cliff calendar, originator estates, attackable patents
- ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer treatment landscape brief
- ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer treatment updates RSS
Frequently asked questions about ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
What drugs treat ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer?
Tracked treatments include Inluriyo.
What is the treatment for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer?
Standard treatment for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer includes Inluriyo. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer patent cliff · ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer CI report
- Treatment: Inluriyo · Eli Lilly And Co
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing